Morgan Stanley tactically bullish on BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs (BHP.US): Over the next two months, two major copper mine catalysts could ignite the stock price.
Morgan Stanley maintains an "Overweight" rating on BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs (BHP.US), with an "Attractive" industry view, and sets its price target for the Australia-listed shares at AUD 69.00.
Morgan Stanley's latest tactical investment report indicates that BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs (BHP.US) is expected to achieve an absolute price increase over the next 60 days (not relative to the broader market, but an increase in the stock price itself), with an estimated probability of approximately 70% to 80% (i.e., "highly likely"). The firm maintains an "Overweight" rating on BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs, with an industry view of "Attractive," and has set a target price of AUD 69.00 for its Australian-listed shares. As of the October 12 close, BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs shares were trading at AUD 62.43, implying approximately 10.5% upside to the target price.
Morgan Stanley analyst Rahul Anand and his team stated in the report that BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs may encounter multiple positive catalysts in the coming months. Among them, the most noteworthy is the company's upcoming investor and analyst site visit to its Copper South Australia (Copper SA) project. The firm believes this event could strengthen market confidence in the scale and timeline of BHP Group Ltd Sponsored American Depositary Receipt Repr 2 Shs's copper growth plans, a factor that current market consensus expectations have not yet fully reflected.
Additionally, the final investment decision (FID) for Phase 1 of the Vicuna copper mine project is expected to be made by the end of 2026, which also constitutes a potential stock price catalyst. Morgan Stanley notes that the aforementioned catalysts could drive the stock price higher in the near term.
Related Articles

Zhuhai Rundu Pharmaceutical (002923.SZ) has received marketing approval for Mosapride Citrate API.

Amid demand doubts, Bank of America stands by Apple Inc. (AAPL.US)! iPhone Duo pre-orders will be a key test.

CICC: Raises TUHU-W (09690) target price, bullish on Australia acquisition opening up overseas growth space.
Zhuhai Rundu Pharmaceutical (002923.SZ) has received marketing approval for Mosapride Citrate API.

Amid demand doubts, Bank of America stands by Apple Inc. (AAPL.US)! iPhone Duo pre-orders will be a key test.

CICC: Raises TUHU-W (09690) target price, bullish on Australia acquisition opening up overseas growth space.






